Plus Therapeutics Highlights Updates On Lead Program In Brain Cancer Indications

• Plus Therapeutics Inc (NASDAQ: PSTV) presented data from two ongoing trials evaluating its lead investigational targeted radiotherapeutic, rhenium (186Re) obisbemeda, in recurrent glioblastoma (GBM), leptomeningeal metastases (LM).

• Data from the first oral presentation included the following key findings:

  • In 24 patients with recurrent glioblastoma, a single dose of rhenium (186Re) obisbemeda was administered in the dose escalation phase, achieving up to 740 Gray (Gy) of absorbed radiation dose to the tumor.

  • No dose-limiting toxicities and a good safety profile have been observed.

  • A statistically significant improvement in overall survival correlated with both the average absorbed dose of radiation to the tumor and the percent volume of tumor treated, specifically:

  • A 100 Gy increase in the absorbed dose correlated with a 35.7% decrease in the risk of death.

  • A 1% increase in tumor volume treated is associated with a 4.5% decrease in the risk of death.

• Related: Plus Therapeutics Shares Surge On Positive Data From Lead Brain Cancer Candidate.

• A recommended Phase 2 dose of 22.3 mCi in 8.8 mL is being studied for tumor volumes of 20 mL or less and is expected to enroll up to an additional 31 patients.

• Data from the second oral presentation in LM patients exhibited that single rhenium (186Re) obisbemeda dose was well tolerated with no treatment-related adverse events greater than grade 1.

  • All four patients treated in Cohorts 1 and 2 were observed to have prompt and complete rhenium (186Re) obisbemeda distribution throughout the cerebrospinal fluid subarachnoid space that was durable to 28 days.

  • All patients showed a decreased CSF tumor cell count by microfluidic chamber assay after treatment, ranging from 46% to 92%.

• Plus Therapeutics will file an Investigational New Drug application for the pediatric Phase 1/2a rhenium (186Re) obisbemeda trial in up to 24 patients with supratentorial recurrent or progressive pediatric ependymoma and high-grade glioma.

• Price Action: PSTV shares closed 4.13% lower at $0.46 on Friday.

See more from Benzinga

• This Analyst Is Bullish On Evolent Health's Recent Deal, Calls 'Highly Strategic Acquisition'

• Pfizer Is Worst-Performing US Large-Cap Pharma Stock This Year, Its Investment Case Is Complex Yet Rewarding

• Desantis Calls Trump 'A Moron Who Has No Business Running For President,' Former Staffers Say: Report

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.